Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment

Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still hig...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lin Tang, Yicheng Feng, Sai Gao, Qingchun Mu, Chaoyong Liu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	glioblastoma blood-brain barrier nanotherapeutics drug delivery nanocarriers Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/f9e438306a1a47058f9d9880affffa4e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9e438306a1a47058f9d9880affffa4e
record_format	dspace
spelling	oai:doaj.org-article:f9e438306a1a47058f9d9880affffa4e2021-12-01T01:17:36ZNanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment1663-981210.3389/fphar.2021.786700https://doaj.org/article/f9e438306a1a47058f9d9880affffa4e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.786700/fullhttps://doaj.org/toc/1663-9812Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still highly needed to improve the therapeutic outcome of GBM treatment. The blood-brain barrier (BBB) is the main barrier that prevents therapeutic drugs from reaching the brain. Nanotechnologies that enable drug delivery across the BBB hold great promise for the treatment of GBM. This review summarizes various drug delivery systems used to treat glioma and focuses on their approaches for overcoming the BBB to enhance the accumulation of small molecules, protein and gene drugs, etc. in the brain.Lin TangLin TangYicheng FengSai GaoQingchun MuChaoyong LiuChaoyong LiuFrontiers Media S.A.articleglioblastomablood-brain barriernanotherapeuticsdrug deliverynanocarriersTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glioblastoma blood-brain barrier nanotherapeutics drug delivery nanocarriers Therapeutics. Pharmacology RM1-950
spellingShingle	glioblastoma blood-brain barrier nanotherapeutics drug delivery nanocarriers Therapeutics. Pharmacology RM1-950 Lin Tang Lin Tang Yicheng Feng Sai Gao Qingchun Mu Chaoyong Liu Chaoyong Liu Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
description	Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still highly needed to improve the therapeutic outcome of GBM treatment. The blood-brain barrier (BBB) is the main barrier that prevents therapeutic drugs from reaching the brain. Nanotechnologies that enable drug delivery across the BBB hold great promise for the treatment of GBM. This review summarizes various drug delivery systems used to treat glioma and focuses on their approaches for overcoming the BBB to enhance the accumulation of small molecules, protein and gene drugs, etc. in the brain.
format	article
author	Lin Tang Lin Tang Yicheng Feng Sai Gao Qingchun Mu Chaoyong Liu Chaoyong Liu
author_facet	Lin Tang Lin Tang Yicheng Feng Sai Gao Qingchun Mu Chaoyong Liu Chaoyong Liu
author_sort	Lin Tang
title	Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
title_short	Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
title_full	Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
title_fullStr	Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
title_full_unstemmed	Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
title_sort	nanotherapeutics overcoming the blood-brain barrier for glioblastoma treatment
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/f9e438306a1a47058f9d9880affffa4e
work_keys_str_mv	AT lintang nanotherapeuticsovercomingthebloodbrainbarrierforglioblastomatreatment AT lintang nanotherapeuticsovercomingthebloodbrainbarrierforglioblastomatreatment AT yichengfeng nanotherapeuticsovercomingthebloodbrainbarrierforglioblastomatreatment AT saigao nanotherapeuticsovercomingthebloodbrainbarrierforglioblastomatreatment AT qingchunmu nanotherapeuticsovercomingthebloodbrainbarrierforglioblastomatreatment AT chaoyongliu nanotherapeuticsovercomingthebloodbrainbarrierforglioblastomatreatment AT chaoyongliu nanotherapeuticsovercomingthebloodbrainbarrierforglioblastomatreatment
_version_	1718406057910337536

Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment

Ejemplares similares